What Is CJC-1295 (no DAC)?

Also known as: Mod GRF 1-29, Modified GRF

CJC-1295 without DAC — properly Modified GRF 1-29 — is a tetrasubstituted analog of the first 29 amino acids of GHRH, the hypothalamic hormone that tells the pituitary to release growth hormone. The four substitutions protect it from rapid enzymatic destruction, stretching a 2-minute natural signal into a ~30-minute one.

It amplifies GH pulses rather than creating them, which is why it is nearly always paired with a pulse-trigger like ipamorelin. The combination targets both receptors of the GH-release system simultaneously — the closest thing peptide protocols have to a standard.

What is CJC-1295 (no DAC) studied for?

Side effects & safety

Flushing, warmth and transient head-rush for a few minutes post-injection are the classic reports. Water retention and mild carpal-tunnel-like symptoms at aggressive doses signal too much GH — the fix is dose reduction.

Legal & approval status

Research chemical; no approvals. WADA-banned. Compounding access restricted in the US.

Typical dosing at a glance

Commonly reported protocols use 100 mcg–200 mcg, 1–3x daily, paired with a GHRP, via subcutaneous injection. For the mixing math — how much bacteriostatic water, exact syringe units, doses per vial — see the CJC-1295 (no DAC) reconstitution calculator →

Related peptides

What is Ipamorelin?What is CJC-1295 DAC?What is Sermorelin?What is Tesamorelin?What is Hexarelin?

Educational overview based on published research and commonly reported community protocols — not medical advice, and not an endorsement of any compound. Consult a licensed healthcare provider.